What we do Sun Pharma Advanced Research Company Ltd (SPARC) is a clinical-stage biopharma firm focused on innovation and new drug development, targeting oncology, immunology, and dermatology worldwide. |
Founded in 2,006 |
Market share SPARC holds a specialized niche in innovative pharmaceutical R&D for global markets with growing clinical assets and partnerships. |
Problem solved SPARC develops novel therapies and drug delivery systems to address critical unmet medical needs in oncology, immunology, and dermatological autoimmune diseases. |
Top clients or who we serve Pharmaceutical partners, global healthcare markets, specialty pharma companies primarily B2B collaborations and licensing. |
Key management Anil Raghavan (CEO) leads a scientifically-driven leadership team with strong expertise in drug development and clinical research. |
Our journey and innovations Founded in 2006, SPARC expanded through strategic licensing, FDA approvals, and pioneering antibody-drug conjugates and immunology assets. |
Where we operate Primarily India and USA with clinical trials and partnerships in Australia, global markets for drug licensing. |
Top products or what we offer Key products include clinical assets SCD-153 (dermatology), SBO-154 (anti-MUC1 ADC for oncology), and partnered ophthalmic drugs like Xelpros. |
Top brands SCD-153 (early-stage topical therapy); SBO-154 (ADC for solid tumors); Xelpros (FDA-approved ophthalmic drug licensed out). |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenues mainly cyclical from drug licensing, royalties, milestone payments; R&D investment intensive with variable income streams. |
Our industry position Emerging innovator in specialty pharma R&D with promising early clinical programs; niche leadership in ADCs and immunology. |
Financial highlights FY2024-25 revenue ₹71.77 crores; net loss ₹342.51 crores reflecting heavy R&D investment phase. |
Geographical revenue split About 70% revenue from India, 2% from outside India; reflecting clinical and licensing activity focus. |
Order book - |
Whats driving growth Pipeline advancement in oncology and immunology, strategic partnerships, regulatory approvals, and cost optimization driving growth potential. |
Our future plans Advancing clinical trials, expanding pipeline in oncology/immunology, exploring NewCos, and optimizing operational costs through 2028. |
Our green promise - |
Our people and values 316 employees, majority highly qualified scientists; focus on talent development, diversity, and a collaborative culture. |
Key challenges ahead Clinical trial risks, regulatory hurdles, capital-intensive R&D, competition in oncology and immunology spaces. |
Interesting facts Holds orphan drug designation and pediatric rare disease voucher opportunities; innovative NewCo model collaborations. |
Risks and strategy Mitigates clinical risks with focused pipeline, alternative financing, and partnerships; strategy centers on sustainable R&D investment. |
